A Study of LY2127399 in Rheumatoid Arthritis

NCT01576549 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Insufficient efficacy observed in study BCDM(NCT01198002) and BCDV(NCT01202773).

Conditions

Rheumatoid Arthritis

Interventions

DRUG: LY2127399

Sponsor

Eli Lilly and Company